Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Cash & Current Investments (2017 - 2025)

Dianthus Therapeutics has reported Cash & Current Investments over the past 8 years, most recently at $346.6 million for Q3 2025.

  • Quarterly results put Cash & Current Investments at $346.6 million for Q3 2025, up 23.3% from a year ago — trailing twelve months through Jun 2025 was $256.1 million (down 29.0% YoY), and the annual figure for FY2024 was $274.4 million, up 57.95%.
  • Cash & Current Investments for Q3 2025 was $346.6 million at Dianthus Therapeutics, up from $256.1 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for DNTH hit a ceiling of $377.0 million in Q1 2024 and a floor of $52.9 million in Q1 2023.
  • Median Cash & Current Investments over the past 4 years was $189.9 million (2023), compared with a mean of $201.6 million.
  • Biggest five-year swings in Cash & Current Investments: crashed 60.38% in 2023 and later surged 612.8% in 2024.
  • Dianthus Therapeutics' Cash & Current Investments stood at $75.5 million in 2022, then soared by 130.12% to $173.7 million in 2023, then surged by 57.95% to $274.4 million in 2024, then increased by 26.32% to $346.6 million in 2025.
  • The last three reported values for Cash & Current Investments were $346.6 million (Q3 2025), $256.1 million (Q2 2025), and $263.2 million (Q1 2025) per Business Quant data.